# Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

> **NCT03044353** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 7 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** GSK2315698 (CPHPC)
- **BIOLOGICAL:** GSK2398852 (anti-SAP mAb)

## Key facts

- **NCT ID:** NCT03044353
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-10
- **Primary completion:** 2019-01-03
- **Final completion:** 2019-01-03
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Change in benefit/risk profile
- **Last updated:** 2019-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03044353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03044353, "Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03044353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*